Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals (Nasdaq: OLMA) has announced new employee stock option grants. Two new employees received a total of 19,800 stock options at $4.21 per share, effective March 3, 2025. Additionally, newly appointed Chief Legal Officer and Corporate Secretary Shawnte Mitchell received 450,000 stock options at $4.37 per share, effective February 28, 2025.
All grants were made under Olema's 2022 Inducement Plan and approved by the Compensation Committee. The options vest over four years, with 25% vesting on the first anniversary and the remainder vesting in 36 monthly installments, subject to continued employment. The options have a 10-year term.
Olema Pharmaceuticals (Nasdaq: OLMA) ha annunciato nuove concessioni di opzioni su azioni per i dipendenti. Due nuovi dipendenti hanno ricevuto un totale di 19.800 opzioni su azioni a $4,21 per azione, con effetto dal 3 marzo 2025. Inoltre, il nuovo Chief Legal Officer e Segretario Aziendale Shawnte Mitchell ha ricevuto 450.000 opzioni su azioni a $4,37 per azione, con effetto dal 28 febbraio 2025.
Tutte le concessioni sono state effettuate nell'ambito del Piano di Induzione 2022 di Olema e approvate dal Comitato Compensi. Le opzioni maturano in quattro anni, con il 25% che matura al primo anniversario e il restante che matura in 36 rate mensili, soggetto a continuazione dell'impiego. Le opzioni hanno una durata di 10 anni.
Olema Pharmaceuticals (Nasdaq: OLMA) ha anunciado nuevas concesiones de opciones sobre acciones para empleados. Dos nuevos empleados recibieron un total de 19,800 opciones sobre acciones a $4.21 por acción, con efecto a partir del 3 de marzo de 2025. Además, el recién nombrado Director Legal y Secretario Corporativo Shawnte Mitchell recibió 450,000 opciones sobre acciones a $4.37 por acción, con efecto a partir del 28 de febrero de 2025.
Todos los otorgamientos se realizaron bajo el Plan de Inducción 2022 de Olema y fueron aprobados por el Comité de Compensación. Las opciones se consolidan durante cuatro años, con el 25% consolidándose en el primer aniversario y el resto consolidándose en 36 cuotas mensuales, sujeto a la continuación del empleo. Las opciones tienen un plazo de 10 años.
Olema Pharmaceuticals (Nasdaq: OLMA)는 새로운 직원 주식 옵션 부여를 발표했습니다. 두 명의 새로운 직원이 각각 주당 $4.21의 가격으로 총 19,800개의 주식 옵션을 받았으며, 이는 2025년 3월 3일부터 유효합니다. 또한, 새로 임명된 법무 책임자 및 기업 비서인 Shawnte Mitchell는 주당 $4.37의 가격으로 450,000개의 주식 옵션을 받았으며, 이는 2025년 2월 28일부터 유효합니다.
모든 부여는 Olema의 2022 유도 계획에 따라 이루어졌으며 보상 위원회의 승인을 받았습니다. 옵션은 4년에 걸쳐 분할 지급되며, 첫 번째 기념일에 25%가 지급되고 나머지는 36개월에 걸쳐 월별로 지급됩니다. 옵션의 유효 기간은 10년입니다.
Olema Pharmaceuticals (Nasdaq: OLMA) a annoncé de nouvelles attributions d'options d'achat d'actions pour les employés. Deux nouveaux employés ont reçu un total de 19 800 options d'achat d'actions à 4,21 $ par action, avec effet au 3 mars 2025. De plus, le nouveau Directeur Juridique et Secrétaire Général Shawnte Mitchell a reçu 450 000 options d'achat d'actions à 4,37 $ par action, avec effet au 28 février 2025.
Toutes les attributions ont été effectuées dans le cadre du Plan d'Induction 2022 d'Olema et approuvées par le Comité de Rémunération. Les options se libèrent sur quatre ans, avec 25 % se libérant au premier anniversaire et le reste se libérant en 36 versements mensuels, sous réserve de la poursuite de l'emploi. Les options ont une durée de 10 ans.
Olema Pharmaceuticals (Nasdaq: OLMA) hat neue Aktienoptionsvergaben für Mitarbeiter angekündigt. Zwei neue Mitarbeiter erhielten insgesamt 19.800 Aktienoptionen zu einem Preis von 4,21 $ pro Aktie, wirksam ab dem 3. März 2025. Darüber hinaus erhielt der neu ernannte Chief Legal Officer und Unternehmenssekretär Shawnte Mitchell 450.000 Aktienoptionen zu einem Preis von 4,37 $ pro Aktie, wirksam ab dem 28. Februar 2025.
Alle Vergaben erfolgten im Rahmen des Olema 2022 Inducement Plans und wurden vom Vergütungsausschuss genehmigt. Die Optionen werden über vier Jahre fällig, wobei 25% am ersten Jahrestag fällig werden und der Rest in 36 monatlichen Raten, vorbehaltlich der Fortsetzung der Beschäftigung. Die Optionen haben eine Laufzeit von 10 Jahren.
- New Chief Legal Officer appointment strengthens executive team
- Stock options align employee interests with shareholders
- Significant potential dilution from 469,800 new stock options
SAN FRANCISCO, March 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to two new employees to purchase an aggregate of 19,800 shares of the Company's common stock, effective as of March 3, 2025. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of
In addition, in connection with the appointment of Shawnte Mitchell as Chief Legal Officer and Corporate Secretary effective February 18, 2025, the Company granted Ms. Mitchell an employment inducement award consisting of stock options to purchase 450,000 shares of the Company’s common stock, with an effective grant date of February 28, 2025 and an exercise price of
Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at www.olema.com.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
FAQ
How many stock options did Olema Pharmaceuticals (OLMA) grant to new employees in March 2025?
What are the vesting terms for Olema's (OLMA) stock option grants announced in March 2025?
How many stock options did Shawnte Mitchell receive as Olema's new Chief Legal Officer?
What is the exercise price for OLMA's stock options granted to new employees in March 2025?
